ArticleESMO gastrointestinal oncology2026
Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.
J Tintelnot et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.